Metraipolis › archive › dc_8d6d016dcdde

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques — Europe PMC PPR:PPR162413

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR162413
DOI
10.1101/2020.05.13.093195
License (as archived)
CC0-1.0
Archived
2026-11-08T18:20:36.393Z
SHA-256 of the archived text
73840880e7740f57536eac15569d33ca3ac25d71b49fb3adb4622801e738d94d
Stable URL of this page
https://metraipolis.com/documento/dc_8d6d016dcdde

How to cite

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques — Europe PMC PPR:PPR162413 — Europe PMC, https://europepmc.org/article/PPR/PPR162413 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_8d6d016dcdde (Metraipolis archive dc_8d6d016dcdde, sha256 73840880e7740f57536eac15569d33ca3ac25d71b49fb3adb4622801e738d94d)
BibTeX
@misc{dc8d6d016dcdde,
  title = {ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques — Europe PMC PPR:PPR162413},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR162413},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_8d6d016dcdde; sha256 73840880e7740f57536eac15569d33ca3ac25d71b49fb3adb4622801e738d94d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR162413. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 2019 1,2 and is responsible for the COVID-19 pandemic 3 . Vaccines are an essential countermeasure urgently needed to control the pandemic 4 . Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was not Th2 dominated, as demonstrated by IgG subclass and cytokine expression profiling. A single vaccination with ChAdOx1 nCoV-19 induced a humoral and cellular immune response in rhesus macaques. We observed a significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated rhesus macaques. Importantly, no evidence of immune-enhanced disease following viral challenge in vaccinated animals was observed. ChAdOx1 nCoV-19 is currently under investigation in a phase I clinical trial. Safety, immunogenicity and efficacy against symptomatic PCR-positive COVID-19 disease will now be assessed in randomised controlled human clinical trials.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: bioRxiv, 2020 (prima pubblicazione 2020-05-13).
Identificativi: DOI 10.1101/2020.05.13.093195.
Pagina: https://europepmc.org/article/PPR/PPR162413 — https://doi.org/10.1101/2020.05.13.093195. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-08T18:17:00.167Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.